Recombinant Human TRAIL R3 (C-6His)

Description

EnkiLife provides the Recombinant Human TRAIL R3 (C-6His) protein,aslo know as Tumor Necrosis Factor Receptor Superfamily Member 10C,Antagonist Decoy Receptor for TRAIL/Apo-2L,Decoy TRAIL Receptor Without Death Domain,Decoy Receptor 1,DcR1,Lymphocyte Inhibitor of TRAIL,TNF-Related Apoptosis-Inducing Ligand Receptor 3,TRAIL Receptor 3,TRAIL-R3,TRAIL Receptor Without an Intracellular Domain,CD263,TNFRSF10C,DCR1,LIT,TRAILR3,TRID, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human TNF-Related Apoptosis-Inducing Ligand Receptor 3 is produced by our Mammalian expression system and the target gene encoding Ala26-Ala221 is expressed with a 6His tag at the C-terminus.Accession:O14798. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:21.78 KDa. Background:Tumor Necrosis Factor Receptor Superfamily Member 10C (TNFRSF10C) is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL with high affinity. TNFRSF10C has the TRAIL-binding extracellular cysteine-rich domains, lacks the intracellular signaling domain. As a result, binding of TRAIL to TRAIL R3 doesn’t transduce an apoptosis signal. The expression of TRAIL R3 gene has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis.